LivePerson, Inc. Securities Class Litigation


Securities class action litigation has been filed on behalf of investors who purchased the publicly traded securities of LivePerson, Inc. (“LivePerson” or the “Company”) (NASDAQ: LPSN) between May 10, 2022 and March 16, 2023, inclusive (the “Class Period”).

If you purchased LivePerson securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than June 23, 2023.  A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff.  You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

LPSN investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff complete the form below, text or email,

Background on the LivePerson Securities Class Litigation

LivePerson, incorporated in Delaware and headquartered in New York, New York, provides conversational mobile and online messaging services to customers. WildHealth is a subsidiary of LivePerson. Wild Health uses algorithms to analyze patients’ genetics and biometrics to provide healthcare advice.

The action alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) LivePerson had material weaknesses with its internal controls that it failed to address; (2) LivePerson failed to disclose that Medicare reimbursement for WildHealth had been suspended before September 30, 2022; and (3) as a result, LivePerson’s revenue attributable to WildHealth’s participation in a Medicare demonstration program for the fourth quarter of 2022 was going to be negatively affected.

On February 28, 2023, before market hours, LivePerson announced that it would be unable to file its Annual Report on Form 10-K with the Securities Exchange Commission (SEC) on time. On this news, the price of LivePerson stock fell $1.69 per share, or 14.31%, to close at $10.12 per share on February 28, 2023.

On March 6, 2023, before market hours, the Company disclosed that it was reviewing WildHealth’s revenue. The Company further disclosed that it anticipated that its review of WildHealth’s revenue would affect the Company’s revenue because WildHealth had been suspended from participating in the Medicare reimbursement program in November 2022. On this news, the price of LivePerson stock fell $0.81 over the next two trading days, or 7.04%, to close at $10.50 on March 7, 2023.

On March 15, 2023, after market hours, the Company announced its financial results for the fourth quarter of 2022. The Company disclosed that its total revenue for the fourth quarter decreased by 1% year-over-year. The Company also disclosed that, as of December 31, 2022, the Company’s internal controls over financial reporting were not effective. On this news, the price of LivePerson stock fell $5.64, or 57.73%, to close at $4.13 per share on March 16, 2023.

Contact us

    First Name (required)

    Last Name (required)

    Email address (required)


    My estimated loss from trading in LivePerson securities stock between May 10, 2022 and present is:

    Under $10,000From $10,000 - $50,000From $50,000 - $100,000Over $100,000


    About Lieff Cabraser

    Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Munich, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $129 billion in verdicts and settlements. Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” In 2021, The American Lawyer named our firm its “Boutique Litigation Firm of the Year.” Benchmark Litigation has named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America,” and listed us as its “2020 California Plaintiff Firm of the Year.” Lieff Cabraser is committed to ensuring access to justice for all.